Ruxolitinib cream + Vehicle
Phase 3Withdrawn 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Hand Eczema
Conditions
Hand Eczema
Trial Timeline
Jan 31, 2023 โ Sep 22, 2024
NCT ID
NCT05219864About Ruxolitinib cream + Vehicle
Ruxolitinib cream + Vehicle is a phase 3 stage product being developed by Incyte for Hand Eczema. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05219864. Target conditions include Hand Eczema.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05906628 | Phase 2 | Completed |
| NCT05219864 | Phase 3 | Withdrawn |
| NCT05233410 | Phase 3 | Withdrawn |
| NCT05127421 | Phase 2 | Completed |
| NCT04057573 | Phase 3 | Completed |
| NCT04052425 | Phase 3 | Completed |
Competing Products
17 competing products in Hand Eczema
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lebrikizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Methylprednisolone Tablet | Johnson & Johnson | Phase 2/3 | 65 |
| ABT-981 + Placebo for ABT-981 | AbbVie | Phase 2 | 52 |
| Pimecrolimus Cream 1% | Novartis | Phase 3 | 77 |
| tocilizumab + saline solution | Roche | Phase 3 | 77 |
| denosumab + Placebo | Amgen | Phase 2 | 51 |
| Dupilumab + Placebo | Sanofi | Phase 2 | 51 |
| dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| clobetasol propionate | GSK plc | Approved | 84 |
| urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smoothยฎ Udder Cream) | Bayer | Phase 2 | 49 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 2 | 49 |
| Ruxolitinib | Incyte | Phase 1/2 | 38 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream | Arcutis Biotherapeutics | Phase 1/2 | 36 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |